N

on-

A

nimal

P

latform

for

Nanoparticle-Based

D

elivery across the blood-brain barrier

I

nterface with

V

ehicle

E

volution

What?

NAP4DIVE aims to reduce animal use in Central Nervous System drug development by up to 95% while saving 30 % of costs.

How?

By identifying nanoparticles for cross-BBB drug delivery and offering avenues for new effective treatment options. This will be done through two complementary non-animal tools: a high-throughput BBB-on-Chip and an in silico model based on machine learning (“Nanoparticle Design Simulator”).
A digital repository of optimized nanoparticle designs “NP Design Library” will be created to gather publicly available and newly obtained NP characterisation data, specialised for BBB delivery. The design simulator screens thousands of NP designs to recommend the most promising ones, which will be tested in vitro on the microfluidic BBB-on-Chip with real-time measurement of barrier integrity. The accuracy and physiological relevance of both tools will be validated by the pharmaceutical partner through comparison with clinical and preclinical data.
A comprehensive HTA will demonstrate market readiness and cost-effectiveness of the tools, an ethical assessment will analyse harm reduction and engagement with regulators and policy makers will promote non-animal alternatives in preclinical testing on a larger scale.